Tango Therapeutics, Inc. (TNGX) Reports In-Line Q1 EPS

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q1 EPS of ($0.36), in-line with the analyst estimate of ($0.36). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $6.73 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal
• NSA lost access to powerful AI model amid Anthropic dispute - NYT